Weston Medical see Intraject flotation:
This article was originally published in Clinica
Executive Summary
Weston Medical, a Cambridge, UK-based company, which has developed the Intraject needle-free liquid injector device, is seeking to raise £50 million ($80 million) on the London Stock Exchange. The company has six licence collaborations with drugs companies for use of its injectors. However, at a recent drug delivery conference, the company's CEO Cristopher Samler predicted that companies such as his only had a 10-year window of opportunity before more sophisticated oral drug formulations reduced the need for needle-free drug delivery (see Clinica No 898, p 15).
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.